› Forums › General Melanoma Community › New research about BRAF Inhibitor Response/No Response
- This topic has 6 replies, 2 voices, and was last updated 12 years, 3 months ago by
JerryfromFauq.
- Post
-
- October 22, 2013 at 11:30 pm
Stumbled on this research focus today. It has to do with biomarkers, signaling pathways and the identification and measurement of a particular protein that MAY early predict and identify those patients who will or will not respond to current BRAF treatment approaches.
Though not definitive by any means; I sure like the focus of the research.
Cheers,
Charlie S
- Replies
-
-
- October 22, 2013 at 11:37 pm
-
- October 22, 2013 at 11:37 pm
-
- October 22, 2013 at 11:37 pm
-
- October 23, 2013 at 3:29 am
Another Step. Will speed things up so much if we learn who should expect postitive results from which treatments. Fionally moving in good directions. Did you see the recent NIH review of cases that found a 47% positive response to IL-2 for NRAS melanoma patients? They also tied IL-2 to having a better response when ones LDH was not real high.
-
- October 23, 2013 at 3:29 am
Another Step. Will speed things up so much if we learn who should expect postitive results from which treatments. Fionally moving in good directions. Did you see the recent NIH review of cases that found a 47% positive response to IL-2 for NRAS melanoma patients? They also tied IL-2 to having a better response when ones LDH was not real high.
-
- October 23, 2013 at 3:29 am
Another Step. Will speed things up so much if we learn who should expect postitive results from which treatments. Fionally moving in good directions. Did you see the recent NIH review of cases that found a 47% positive response to IL-2 for NRAS melanoma patients? They also tied IL-2 to having a better response when ones LDH was not real high.
-
- You must be logged in to reply to this topic.